Merck Says Data Positive From Keytruda Breast Cancer Study
July 15 2021 - 2:24PM
Dow Jones News
By Michael Dabaie
Merck & Co. Inc. said it had positive event-free survival
data from the Phase 3 Keynote-522 study of Keytruda.
The Keynote-522 trial investigated Keytruda plus chemotherapy
followed by Keytruda as monotherapy, compared with chemotherapy
followed by a placebo in patients with high-risk early-stage
triple-negative breast cancer. Triple-negative breast cancer is an
aggressive type of breast cancer that characteristically has a high
recurrence rate within the first five years after diagnosis, the
company said.
Merck said Keytruda plus chemotherapy before surgery and
continued as a single agent after surgery showed statistically
significant event-free survival results versus chemotherapy
alone.
Merck defined event-free survival as the time from randomization
to the first occurrence of either disease progression that
precluded surgery, a recurrence in the same place as the original
cancer or spread to far organs or tissues, a second primary cancer,
or death from any cause.
After a median follow-up of 39 months, the Keytruda regimen
reduced the risk of EFS events by 37% versus the
chemotherapy-placebo regimen. Merck said this is a statistically
significant and clinically meaningful EFS result.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
July 15, 2021 14:22 ET (18:22 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024
